The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Objectives
We sought to evaluate the effectiveness and safety of rivaroxaban vs apixaban in non‐valvular atrial fibrillation (NVAF) patients with end‐stage renal disease (ESRD) and/or receiving dialysis in routine practice.
Methods
Using US MarketScan claims data from January 1, 2014, to December 31, 2017, we identified new‐users of rivaroxaban or apixaban during 2015 with at least 12 months of...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.